← all works
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Canadian affiliationAn author listed a Canadian institution. This is the only route the usual frame has.
Abstract
No abstract. This is not a gap in this database — OpenAlex has none either. 23.3% of the frame is in this state, and the screen finds HALF as much metaresearch here, so the absence is a measured bias rather than a missing field.
The record
- Venue
- The Lancet Oncology
- Topic
- Advanced Breast Cancer Therapies
- Field
- Medicine
- Canadian institutions
- Sunnybrook Health Science CentreUniversity of Calgary
- Funders
- University of California, Los AngelesNovartisDaiichi-SankyoPfizerAstraZenecaEli Lilly and CompanyGlaxoSmithKlineU.S. Department of Defense
- Keywords
- FulvestrantPalbociclibMetastatic breast cancerMedicinePlaceboInternal medicineOncologyGynecologyCancerBreast cancerEstrogen receptor
- Has abstract in OpenAlex
- no